Skip to content
The Nexus
BUSINESSJun 9 · 02:17 UTCFINANCIAL TIMES WORLD

GSK in talks to buy cancer biotech Nuvalent for more than $9bn

GSK is in talks to acquire cancer biotech Nuvalent for more than $9 billion. The deal would rank as one of the UK drugmaker’s largest as biotech M&A activity accelerates this year.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
GSKorganizationNuvalentorganizationbiotechtopicM&A activitytopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting